
|Articles|June 16, 2022
Science 37 Publishes New Data From Oncology Clinical Research Executives
Almost three in four (73%) oncology research executives plan to execute either a fully decentralized or hybrid clinical trial in the next 12 months.
Advertisement
Science 37 published new data from oncology clinical research executives, indicating three-quarters of all planned new oncology study starts over the next 12 months will include elements of decentralization.
Among the findings:
- The biggest perceived challenges with traditional oncology clinical trials (including both traditional studies and agile/DCTs) are Patient Recruitment (72% of execs ranked it in their top three), Study Start-Up (55%), and Timeline/Delays (54%).
- The top three perceived benefits of using agile/DCT tools in oncology trials are Increased Patient Retention (which 67% of respondents ranked in their top three), Greater Patient Diversity (54%), and Faster Patient Recruitment (50%).
Read more about the data
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement